FDA Clears Nexpowder Endoscopic Hemostasis System

Megan Brooks

September 29, 2022

The US Food and Drug Administration has cleared the Nexpowder endoscopic hemostasis system.

Nexpowder (Medtronic) uses a noncontact, nonthermal, nontraumatic hemostatic powder that is sprayed through a catheter and that features a proprietary powder-coating technology that helps reduce clogging.

This provides improved visibility and control for treating upper gastrointestinal (GI) nonvariceal bleeding, the company explains in a news release.

Nexpowder is sprayed directly on a target site endoscopically through a catheter that connects to a spray handle. Upon contact, it forms a muco-adhesive, durable gel, with or without blood, which degrades in 1 to 3 days.

Because it doesn't require CO2 or air compressors, the Nexpowder endoscopic hemostasis system "combats the inefficiency of clogged catheters and cloudy fields of vision with a proprietary hydrophilic polymer to enable controlled delivery, minimize catheter clogging and maintain endoscopic visibility," the company explains.

In testing, Nexpowder demonstrated a 94% immediate hemostasis rate and a 3.7% rebleeding rate.

More than 1 million endoscopic hemostasis procedures are performed each year in the United States. Upper GI bleeding is one of the most common causes, accounting for 75% of all acute GI bleeding cases, according to Medtronic.

For more news, follow Medscape on Facebook, Twitter, Instagram, and YouTube.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.